Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher versus standard adalimumab dosing in moderately to severely active ulcerative colitis
2013-001682-16Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical remission at Week 8 (Induction Study). Started Apr 2014; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-001682-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001682-16.